Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Glioblastoma 3Carcinoma, Hepatocellular 3Prostatic Neoplasms 2Liver Neoplasms 2Hemangiosarcoma 2Glioma 2Choriocarcinoma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Trophoblastic Tumor, Placental Site 1Sarcoma 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasms 1Liver Neoplasms, Experimental 1Gliosarcoma 1Gestational Trophoblastic Disease 1Fallopian Tube Neoplasms 1Disease Progression 1Carcinoma, Transitional Cell 1Brain Neoplasms 1Astrocytoma 1Adult Solid Tumor 1Adenoma, Liver Cell 1

Interventions

Sunitinib 64Nivolumab 42pembrolizumab 36Bevacizumab 32Everolimus 31Sorafenib 25pazopanib 23Axitinib 23cabozantinib 14aldesleukin 13Ipilimumab 13temsirolimus 11Interferon alpha-2 11Cyclophosphamide 10avelumab 9Magnetic Resonance Spectroscopy 9Interleukin-2 9lenvatinib 8atezolizumab 8Radiosurgery 8Gemcitabine 8Immunoglobulin G 7Erlotinib Hydrochloride 7Disulfides 6fludarabine phosphate 5Radiotherapy 5Fluorodeoxyglucose F18 5peginterferon alfa-2b 4Vorinostat 4Tyrosine Kinase Inhibitors 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Carcinoma, Renal Cell × carotuximab × Clear all
NCT01806064 2020-10-19

Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma

Tracon Pharmaceuticals Inc.

Phase 1/2 Terminated
173 enrolled 17 charts
Genitourinary

Carcinoma, Renal Cell

NCT01727089 2018-08-28

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Completed
59 enrolled 12 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡